Blockchain Registration Transaction Record

Lantern Pharma Secures Key Patent for LP-284 in Blood Cancers

Lantern Pharma (LTRN) secures USPTO patent allowance for LP-284 in mantle cell lymphoma and double-hit lymphoma, extending IP protection to 2042.

This patent allowance is a significant milestone for Lantern Pharma, as it strengthens the intellectual property protection for LP-284, a promising therapy for mantle cell lymphoma and double-hit lymphoma—aggressive blood cancers with limited treatment options. The extension of patent protection into 2042 provides a longer exclusivity period, potentially enhancing the drug's commercial value and attracting investment. Moreover, the method-of-use claims covering LP-284 both as a monotherapy and in combination with other anti-cancer agents could broaden its therapeutic applications and increase its market potential. For patients, this development signals progress toward new treatment options for underserved blood cancers. For investors, it underscores Lantern's commitment to advancing its pipeline and leveraging its AI platform to bring precision oncology therapies to market efficiently.